ATLANTA & MIAMI — Amniox Medical, Inc. (“Amniox”, the “Company”), a leading provider of amniotic membrane based products for wound care and reconstructive surgery, today announced that Thomas J. Dugan has joined the Company as Chief Executive Officer. Mr. Dugan previously joined the Amniox Medical Board of Directors in 2014.
Amy Tseng, Founder and CEO of TissueTech, Inc., the parent company of Amniox, commented, “We are very pleased to have Tom join Amniox as Chief Executive Officer. Tom brings a wealth of experience in the medical device industry and an impressive track record in the wound care market. There he drove significant revenue growth in the face of challenging competition. Under Aaron Smith, General Manager of Amniox, we have built a strong position in the surgical and wound care markets. We believe that Tom is the right person to lead and strengthen the management team at Amniox as we grow our business and maintain our unique position in characterizing and preserving the biology and functionality of human amniotic membrane and umbilical cord to deliver the benefits of regenerative healing across a wide variety of patients.”
“I am joining Amniox at a pivotal and exciting moment for the organization,” said Mr. Dugan. “We have had tremendous growth in both the wound care and surgical markets, and I am confident my partnership with Aaron and his team will be characterized by success. Additionally, with our industry leadership position as the only provider of a human tissue matrix composed of both umbilical cord and amniotic membrane, we can continue to accelerate the growth of the Company.” 
Prior to his arrival at Amniox, Mr. Dugan was President and a member of the board of directors of SurgiQuest, Inc. From 2008 until 2013, he served as President, North America, of Smith & Nephew Wound Management (LSE: SN, NYSE: SNN) and served on the Global Executive Management team of Smith & Nephew’s $1.3 billion wound management business. At Smith & Nephew, he led the turnaround of the North American business, driving growth at over twice the market rate, and established Smith & Nephew as a leading player in the Negative Pressure Wound Therapy market against the dominant market leader. Previously, Mr. Dugan served as the Senior Vice President of Sales & Marketing for SonoSite, Inc., the world leader in hand carried ultrasound. Mr. Dugan also served as President of InterVascular, Inc. and Corporate Vice President of Business Development of Datascope. He was the Vice President of Marketing and ran business development for U.S. Surgical/Tyco Healthcare (now Covidien) during a period of significant M&A activity. Earlier in his career, Mr. Dugan held various sales, marketing and international positions with C.R. Bard, Puritan-Bennett and Johnson & Johnson. He also served on the Board of Directors of RITA Medical Systems, Inc. and two other venture backed medical device companies. Mr. Dugan was previously the Chair of the Wound Healing and Tissue Regeneration Sector of AdvaMed and was on the Board of the Medical Imaging Trade Association (MITA).
About Amniox Medical, Inc.
Founded in 2011 to serve the orthopedic and wound care markets, AMNIOX Medical is dedicated to developing and marketing regenerative therapies processed from amniotic membrane and umbilical cord matrix utilizing its proprietary CRYOTEK technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. AMNIOX Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visithttp://www.amnioxmedical.com.
About TissueTech, Inc.
TissueTech, Inc., the parent company of both Amniox Medical, Inc. and BioTissue, Inc., is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, more than 160,000 human implants have been conducted using the Company’s patented CRYOTEK process and 300 peer-reviewed scientific publications have been produced supporting the technology platform. The Company has pioneered the clinical application of human amniotic membrane and its role in mesenchymal stem cell research. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.